Abstract:OBJECTIVE:To explore the expression and clinical significance of chemokine CXCL10 and CXCR3 in hepatocellular carcinoma (HCC). METHODS:The expression and prognostic of CXCL10 and CXCR3 in HCC tumor tissues and non-tumor tissues were analyzed in two different publicly available databases the Cancer Genome Atlas (TCGA) and Liver Cancer Institute (LCI). In addition, quantitative real-time PCR (qPCR) was used to detect the mRNA expression of CXCL10 and CXCR3 in 45 HCC clinical samples with HBV infection background. Pearson correlation and Spearman rank correlation were used to determine the correlation between the expression level of CXCL10 and CXCR3 in tumor and non-tumor tissues. RESULTS:In TCGA database, the expression of CXCL10 in HCC tumor tissues was significantly higher than that in non-tumor tissues (nonpaired samples: 3.379±2.081 vs. 2.213±2.274, P<0.001; paired samples: 3.159±2.267 vs. 2.213±2.274, P=0.018). Similarly in LCI datebase (7.625±1.683 vs. 7.287±1.328, P=0.009). And higher CXCL10 expression was significantly associated with a better prognosis in the patients with HCC both in TCGA and LCI database (P=0.107, P=0.002). In TCGA database, the expression of CXCR3 in HCC tumor tissues was significantly higher than that in non-tumor tissues (nonpaired samples: -0.906±1.697 vs. -1.978±1.629, P<0.001; paired samples: -1.329±1.732 vs. -1.978±1.629, P=0.037), while lower in LCI database (3.989±0.339 vs. 4.074±0.309, P=0.003). In both databases, higher CXCR3 expression was significantly associated with a better prognosis in the HCC patients (P=0.004, P=0.014). Furthermore, in TCGA database, the expression level of CXCL10 and CXCR3 was positively correlated both in HCC tumor tissues and matched non-tumor tissues (r=0.584, P<0.001; r=0.776, P<0.001). The qPCR assay showed that the expression of CXCL10 in HBV-related HCC tumor tissues was significantly higher than those in normal liver tissues [0.479(0.223, 1.094) vs. 0.131(0.106, 0.159), P=0.010], and the expression in HBV-related non-tumor tissues was also significantly higher than those in normal liver tissues [0.484(0.241, 0.846) vs. 0.131(0.106, 0.159), P<0.001]. The same was true as CXCR3 [0.011(0.006, 0.019) vs. 0.002(0.001, 0.004), P=0.004; 0.016(0.011, 0.021) vs. 0.002(0.001, 0.004), P<0.001]. However there was no significant difference of CXCL10 and CXCR3 between tumor tissues and matched non-tumor tissues (P=1.000, P=0.374). CONCLUSION:Expression of CXCL10 was up-regulated in HCC tissues, expression of CXCR3 was down-regulated in HBV-related HCC tissues, and the higher expression of both genes was correlated with better overall survival in HCC patients.

Abnormal Beta-Catenin Gene Expression with Invasiveness of Primary Hepatocellular Carcinoma in China

Mutation and Overexpression of the Β-Catenin Gene May Play an Important Role in Primary Hepatocellular Carcinoma among Chinese People

Expression and clinical significance of GS,E-cadherin and β-catenin in hepatocellular carcinoma

Expression of BC047440 gene in human hepatocellular carcinoma tissues and its significance

BC047440 Overexpression is a Risk Factor for Tumor Invasion and Poor Prognosis in Hepatocellular Carcinoma.

[Expression and Exon 3 Mutation of Beta-Catenin in Human Hepatocellular Carcinoma].

Wnt Signaling in Hepatocellular Carcinoma: Analysis of Mutation and Expression of Beta-Catenin, T-cell Factor-4 and Glycogen Synthase Kinase 3-Beta Genes.

Expression of SRF, E-cadherin and β-catenin in hepatocellular carcinoma and its clinical significances

Β-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma

Cytoplasmic And/or Nuclear Expression of Β-Catenin Correlate with Poor Prognosis and Unfavorable Clinicopathological Factors in Hepatocellular Carcinoma: a Meta-Analysis.

Increased Sensitivity To Wnt/Beta-Catenin Inhibitors In Hepatocellular Carcinoma Cells Harboring Activating Mutation Of Beta-Catenin

Alterations of Beta-Catenin and Tcf-4 Instead of Gsk-3 Beta Contribute to Activation of Wnt Pathway in Hepatocellular Carcinoma

Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.

Beta-Catenin Expression Pattern in Primary Oral Squamous Cell Carcinoma

Overexpressions of Ck2 Beta and Xiap Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

Association of Htcf—4 Gene Expression and Mutation with Clinicopathological Characteristics of Hepatocellular Carcinoma

Expression of Beta-Catenin in Renal Cell Carcinoma

[Relationship Between Abnormal Expression of Beta-Catenin in Gastric Carcinoma and Survival].

[Real-Time PCR Analysis of Beta-Catenin Mrna in Sporadic Colorectal Cancers].

[Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma].

[Expression of Beta-Catenin in Human Colorectal Adenoma and Carcinoma].